ME02413B - Postupak lečenja proliferativnih oboljenja i drugih patoloških stanja posredovanih aktivnoscu bcr-abl, c-kit, ddr1, ddr2 ili pdgf-r kinaze - Google Patents
Postupak lečenja proliferativnih oboljenja i drugih patoloških stanja posredovanih aktivnoscu bcr-abl, c-kit, ddr1, ddr2 ili pdgf-r kinazeInfo
- Publication number
- ME02413B ME02413B MEP-2016-89A MEP8916A ME02413B ME 02413 B ME02413 B ME 02413B ME P8916 A MEP8916 A ME P8916A ME 02413 B ME02413 B ME 02413B
- Authority
- ME
- Montenegro
- Prior art keywords
- formula
- pyrimidylaminobenzamide
- pharmaceutically acceptable
- kinase activity
- kit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/69—Benzenesulfonamido-pyrimidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (3)
1. Pirimidilaminobenzamid formule (I)u kojojPy označava 3-piridil,R1 predstavlja vodonik,R2 predstavlja 5-(4-metil-1H-imidazol-1-il)-3-(trifluorometil)-fenil; iR4 predstavlja metil;ili njegova farmaceutski prihvatljiva so, za lečenje proliferativnog oboljenja ili drugih patoloških stanja odabranih iz grupe koju čine melanom, posebno melanom koji u svom sastavu ima skrivene c-KIT mutacije, karcinom dojke, kancer debelog creva, kancer pluća, kancer prostate ili Kapošijev sarkom, gastrointestinalni stromalni tumori (GIST), akutna mijeloidna leukemija (AML), leukemija koja odgovara na inhibiciju aktivnosti Abl tirozin kinaze, hronična mijeloidna leukemija (CML), Filadelfija hromozom pozitivna akutna limfoblastna leukemija (Ph+ ALL), mezoteliom, sistemska mastocitoza, hipereozinofilni sindrom (HES), fibroza, hepatska fibroza, renalna fibroza, reumatoidni artritis, poliartritis, skleroderma, lupus eritematozus, bolest kalema protiv domaćina, neurofibromatoza, pulmonarna hipertenzija, pulmonarna arterijska hipertenzija, Alchajmerova bolest, seminom, disgerminom i psorijaza, gde se jedinjenje formule (I) ili njena farmaceutski prihvatljiva so i, po slobodnom izboru, farmaceutski prihvatljivi nosači, oralno primenjuju pomešani sa pireom od jabuke.
2.Pirimidilaminobenzamid formule (I) za upotrebu prema patentnom zahtevu 1 u obliku njegove monohidrohloridne monohidratne soli.
3. Pirimidilaminobenzamid formule (I) ili pirimidilaminobenzamid formule (I) u obliku njegove monohidrohloridne monohidratne soli za upotrebu prema patentnom zahtevu 1, naznačen time, što je patološko stanje odabrano od CML i Ph+ ALL. 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26181209P | 2009-11-17 | 2009-11-17 | |
| PCT/US2010/056926 WO2011062927A1 (en) | 2009-11-17 | 2010-11-17 | Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity |
| EP10781781.9A EP2501384B2 (en) | 2009-11-17 | 2010-11-17 | Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02413B true ME02413B (me) | 2016-09-20 |
Family
ID=43513643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-89A ME02413B (me) | 2009-11-17 | 2010-11-17 | Postupak lečenja proliferativnih oboljenja i drugih patoloških stanja posredovanih aktivnoscu bcr-abl, c-kit, ddr1, ddr2 ili pdgf-r kinaze |
Country Status (37)
| Country | Link |
|---|---|
| US (1) | US9061029B2 (me) |
| EP (1) | EP2501384B2 (me) |
| JP (2) | JP5829615B2 (me) |
| KR (1) | KR101743315B1 (me) |
| CN (1) | CN102612368B (me) |
| AR (1) | AR079029A1 (me) |
| AU (1) | AU2010322102B2 (me) |
| BR (1) | BR112012011693A2 (me) |
| CA (1) | CA2779490C (me) |
| CL (1) | CL2012001270A1 (me) |
| CO (1) | CO6551690A2 (me) |
| DK (1) | DK2501384T4 (me) |
| EC (1) | ECSP12011903A (me) |
| ES (1) | ES2572128T5 (me) |
| FI (1) | FI2501384T4 (me) |
| GT (1) | GT201200150A (me) |
| HR (1) | HRP20160472T4 (me) |
| HU (1) | HUE027307T2 (me) |
| IL (1) | IL219727A (me) |
| JO (1) | JO3634B1 (me) |
| MA (1) | MA33738B1 (me) |
| ME (1) | ME02413B (me) |
| MX (1) | MX2012005694A (me) |
| MY (1) | MY169956A (me) |
| NZ (1) | NZ599968A (me) |
| PE (1) | PE20121476A1 (me) |
| PH (1) | PH12012500965A1 (me) |
| PL (1) | PL2501384T5 (me) |
| RS (1) | RS54747B2 (me) |
| RU (1) | RU2625835C2 (me) |
| SG (1) | SG10201501169VA (me) |
| SI (1) | SI2501384T2 (me) |
| SM (1) | SMT201600143B (me) |
| TN (1) | TN2012000206A1 (me) |
| TW (1) | TWI498116B (me) |
| WO (1) | WO2011062927A1 (me) |
| ZA (1) | ZA201203328B (me) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013068836A1 (en) | 2011-11-07 | 2013-05-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A ddr1 antagonist or an inhibitor of ddr1 gene expression for use in the prevention or treatment of crescentic glomerulonephritis |
| BR112014026266A2 (pt) | 2012-04-24 | 2017-06-27 | Chugai Pharmaceutical Co Ltd | derivado de quinazolidinadiona |
| BR112014026305A2 (pt) * | 2012-04-24 | 2017-06-27 | Chugai Pharmaceutical Co Ltd | derivado de quinazolidinadiona |
| WO2013166295A1 (en) | 2012-05-02 | 2013-11-07 | Georgetown University | Treating neural disease with tyrosine kinase inhibitors |
| PT2861579T (pt) * | 2012-05-15 | 2018-04-27 | Novartis Ag | Derivados de benzamida para inibir a atividade de abl1, abl2 e bcr-abl |
| US9561245B2 (en) | 2012-09-06 | 2017-02-07 | The Board Of Regents Of The University Of Texas System | Combination treatments for melanoma |
| US20140080772A1 (en) * | 2012-09-06 | 2014-03-20 | The Board Of Regents Of The University Of Texas System | Treatments for melanoma |
| US9572828B2 (en) | 2013-07-18 | 2017-02-21 | The Board Of Regents Of The University Of Texas System | Treatment for melanoma |
| US10005739B2 (en) | 2013-10-23 | 2018-06-26 | Chugai Seiyaku Kabushiki Kaisha | Quinazolinone and isoquinolinone derivative |
| WO2017038871A1 (ja) * | 2015-08-31 | 2017-03-09 | 東レ株式会社 | 尿素誘導体及びその用途 |
| CN108103186B (zh) * | 2018-02-28 | 2021-07-02 | 固安博健生物技术有限公司 | 诊断类风湿性关节炎和骨关节炎的分子标志物 |
| CN120305263A (zh) | 2018-06-15 | 2025-07-15 | 汉达癌症医药责任有限公司 | 卡博替尼的盐类于制备治疗癌症的剂型的用途 |
| CN113272308B (zh) | 2018-11-20 | 2025-03-18 | 乔治敦大学 | 用于治疗神经退行性、肌退行性和溶酶体贮积病症的组合物和方法 |
| WO2020144647A1 (en) * | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Pharmaceutical composition comprising apalutamide dispersed in apple sauce |
| EP4096791A1 (en) | 2020-01-31 | 2022-12-07 | Nanocopoeia LLC | Amorphous nilotinib microparticles and uses thereof |
| IL297776A (en) | 2020-04-30 | 2022-12-01 | Nanocopoeia Llc | Orally disintegrating tablets containing an amorphous solid dispersion of nalotinib |
| MX2023003556A (es) | 2020-09-29 | 2023-06-13 | Shenzhen Pharmacin Co Ltd | Composiciones farmaceuticas. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7494997B2 (en) | 2002-06-28 | 2009-02-24 | Nippon Shinyaku Co., Ltd. | Amide derivative |
| GB0215676D0 (en) * | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| CN1802152A (zh) | 2002-08-01 | 2006-07-12 | 艾斯根公司 | 用谷氨酰胺改善癌症的治疗 |
| CN103638028A (zh) * | 2005-05-02 | 2014-03-19 | 诺瓦提斯公司 | 嘧啶基氨基苯甲酰胺衍生物用于治疗全身性肥大细胞增多症的应用 |
| SA06270147B1 (ar) | 2005-06-09 | 2009-12-22 | نوفارتيس ايه جي | عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين |
| GT200600315A (es) | 2005-07-20 | 2007-03-19 | Formas cristalinas de 4-metilo-n-[3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo]-3-(4-pyridina-3-ilo-pirimidina-2-iloamino)-benzamida | |
| GT200600316A (es) | 2005-07-20 | 2007-04-02 | Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida. | |
| EP1923053A1 (en) | 2006-09-27 | 2008-05-21 | Novartis AG | Pharmaceutical compositions comprising nilotinib or its salt |
| KR100925559B1 (ko) | 2007-10-26 | 2009-11-05 | 한국과학기술연구원 | 악티노마이신 ｄ를 유효성분으로 하는 ｄｄｒ과 콜라겐결합 저해제 |
-
2010
- 2010-11-14 JO JOP/2010/0396A patent/JO3634B1/ar active
- 2010-11-15 AR ARP100104212A patent/AR079029A1/es not_active Application Discontinuation
- 2010-11-16 TW TW099139425A patent/TWI498116B/zh active
- 2010-11-17 EP EP10781781.9A patent/EP2501384B2/en active Active
- 2010-11-17 US US13/509,626 patent/US9061029B2/en active Active
- 2010-11-17 NZ NZ599968A patent/NZ599968A/en not_active IP Right Cessation
- 2010-11-17 SI SI201031172T patent/SI2501384T2/sl unknown
- 2010-11-17 RS RS20160303A patent/RS54747B2/sr unknown
- 2010-11-17 SG SG10201501169VA patent/SG10201501169VA/en unknown
- 2010-11-17 CN CN201080051819.0A patent/CN102612368B/zh not_active Ceased
- 2010-11-17 RU RU2012124811A patent/RU2625835C2/ru active
- 2010-11-17 KR KR1020127012603A patent/KR101743315B1/ko active Active
- 2010-11-17 DK DK10781781.9T patent/DK2501384T4/da active
- 2010-11-17 PL PL10781781.9T patent/PL2501384T5/pl unknown
- 2010-11-17 BR BR112012011693A patent/BR112012011693A2/pt not_active Application Discontinuation
- 2010-11-17 MX MX2012005694A patent/MX2012005694A/es active IP Right Grant
- 2010-11-17 ME MEP-2016-89A patent/ME02413B/me unknown
- 2010-11-17 JP JP2012539982A patent/JP5829615B2/ja active Active
- 2010-11-17 PE PE2012000667A patent/PE20121476A1/es not_active Application Discontinuation
- 2010-11-17 HR HRP20160472TT patent/HRP20160472T4/hr unknown
- 2010-11-17 HU HUE10781781A patent/HUE027307T2/hu unknown
- 2010-11-17 CA CA2779490A patent/CA2779490C/en active Active
- 2010-11-17 FI FIEP10781781.9T patent/FI2501384T4/fi active
- 2010-11-17 ES ES10781781T patent/ES2572128T5/es active Active
- 2010-11-17 AU AU2010322102A patent/AU2010322102B2/en active Active
- 2010-11-17 MY MYPI2012001993A patent/MY169956A/en unknown
- 2010-11-17 WO PCT/US2010/056926 patent/WO2011062927A1/en not_active Ceased
- 2010-11-17 PH PH1/2012/500965A patent/PH12012500965A1/en unknown
-
2012
- 2012-05-07 TN TNP2012000206A patent/TN2012000206A1/en unknown
- 2012-05-08 ZA ZA2012/03328A patent/ZA201203328B/en unknown
- 2012-05-10 IL IL219727A patent/IL219727A/en active IP Right Grant
- 2012-05-11 MA MA34855A patent/MA33738B1/fr unknown
- 2012-05-16 EC ECSP12011903 patent/ECSP12011903A/es unknown
- 2012-05-16 CL CL2012001270A patent/CL2012001270A1/es unknown
- 2012-05-17 GT GT201200150A patent/GT201200150A/es unknown
- 2012-05-17 CO CO12081907A patent/CO6551690A2/es not_active Application Discontinuation
-
2015
- 2015-04-28 JP JP2015091857A patent/JP2015180636A/ja active Pending
-
2016
- 2016-05-23 SM SM201600143T patent/SMT201600143B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20160472T1 (hr) | Postupak liječenja proliferativnih bolesti i ostalih patoloških stanja posredovanih djelovanjem kinaze od bcr-abl, c-kit, ddr1, ddr2 ili pdgf-r | |
| JP2017511311A5 (me) | ||
| JP2015529235A5 (me) | ||
| Shi et al. | Discovery of N-(2-phenyl-1H-benzo [d] imidazol-5-yl) quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors | |
| RU2018100142A (ru) | Гетероциклические соединения, эффективные для ингибирования киназы | |
| Mao et al. | Design, synthesis and biological evaluation of novel pyrimidine, 3-cyanopyridine and m-amino-N-phenylbenzamide based monocyclic EGFR tyrosine kinase inhibitors | |
| JP2017088633A5 (me) | ||
| RU2017125025A (ru) | Конденсированные кольцевые гетероарильные соединения и их применение в качестве ингибиторов trk | |
| MX2010007604A (es) | Pirimidinas como inhibidores de cinasa. | |
| RU2012120901A (ru) | Способ лечения пролиферативных расстройств и других патологических состояний, опосредованных действием киназ bcr-abl, c-kit, ddr1, ddr2 или pdgf-r | |
| CA2606719A1 (en) | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same | |
| JP2012526766A5 (me) | ||
| US20080255171A1 (en) | Combination of Nilotinib with Farnesyl Transferase Inhibitors | |
| CN110891950A (zh) | 一种三嗪化合物及其药学上可接受的盐 | |
| ME02834B (me) | N-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamid i n-(4-hidroksi-4-metilcikloheksil)- 4-(2-piridil)benzensulfonamid i nihova terapijska upotreba | |
| RU2015153319A (ru) | Гетероциклическое соединение бензимидазол-2-пиперазин, его фармацевтическая композиция, а также препаративные методы и назначение | |
| Yang et al. | Synthesis and biological evaluation of novel thieno [2, 3-d] pyrimidine-based FLT3 inhibitors as anti-leukemic agents | |
| NZ590177A (en) | Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis | |
| JP2024125139A5 (me) | ||
| CN109232467B (zh) | 噻唑氨基苯甲酸衍生物及其用途 | |
| CN106957242A (zh) | 一种希夫碱类化合物及其制备方法和制药用途 | |
| RU2011153613A (ru) | Аминопиразол триазолотиадиазольные ингибиторы протеинкиназы с-мет | |
| MX389229B (es) | Nuevas formas de sal cristalina de 3-(1,2,4-triazolo[4,3-a]piridin-3-iletinil)-4-metil-n-(4-((4-metilpiperazin-1-il)metil)-3-trifluorometilfenil)benzamida para aplicacion medica. | |
| JP2012526767A5 (me) | ||
| HRP20210359T1 (hr) | Spojevi aminotiolestera ili njihove farmaceutski prihvatljive soli, za upotrebu u liječenju raka |